Patents by Inventor Harald Bluhm
Harald Bluhm has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8835441Abstract: The present invention relates generally to amide containing heterobicyclic compounds having the following formulas: wherein R1, R2, D, and Q are as defined in the specification. More particularly, the present invention provides a new class of amide containing heterobicyclic compounds, that exhibit an increased potency in relation to currently known MMP-13 and MMP-3 inhibitors.Type: GrantFiled: June 17, 2011Date of Patent: September 16, 2014Assignee: Amgen Inc.Inventors: Christoph Steeneck, Christian Gege, Frank Richter, Heiko Kroth, Matthias Hochgürtel, Michael Essers, Joshua van Veldhuizen, Bert Nolte, Brian M. Gallagher, Jr., Tim Feuerstein, Matthias Schneider, Torsten Arndt, Hongbo Deng, Ralf Biesinger, Xinyuan Wu, Harald Bluhm, Irving Sucholeiki, Arthur G. Taveras
-
Publication number: 20120015920Abstract: The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic MMP-13 inhibiting and MMP-3 inhibiting compounds, that exhibit an increased potency in relation to currently known MMP-13 and MMP-3 inhibitors.Type: ApplicationFiled: June 17, 2011Publication date: January 19, 2012Applicant: Alantos Pharmaceuticals Holding, Inc.Inventors: Christoph Steeneck, Christian Gege, Frank Richter, Heiko Kroth, Matthias Hochgürtel, Michael Essers, Joshua van Veldhuizen, Bert Nolte, Brian M. Gallagher, JR., Tim Feuerstein, Matthias Schneider, Torsten Arndt, Hongbo Deng, Ralf Biesinger, Xinyuan Wu, Harald Bluhm, Irving Sucholeiki, Arthur G. Taveras
-
Publication number: 20100249102Abstract: The present invention relates generally to azatriocyclic containing pharmaceutical agents, and in particular, to azatricyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of azatricyclic MMP-3, MMP-8 and/or MMP-13 inhibiting compounds, that exhibit an increased potency and selectivity in relation to currently known MMP-13, MMP-8 and MMP-3 inhibitors.Type: ApplicationFiled: April 6, 2010Publication date: September 30, 2010Applicant: ALANTOS PHARMACEUTICALS HOLDINGS, INC.Inventors: Christian Gege, Carine Chevrier, Matthias Schneider, Harald Bluhm, Matthias Hochgürtel, Hongbo Deng, Brian M. Gallagher, JR., Irving Sucholeiki, Arthur Taveras
-
Patent number: 7795245Abstract: The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds having the following formulas: wherein R1, R2, R3, and R4 are as defined in the specification. More particularly, the present invention provides a new class of heterobicyclic MMP-13 inhibiting and MMP-3 inhibiting compounds amide containing heterobicyclic compounds, that exhibit an increased potency in relation to currently known MMP-13 and MMP-3 inhibitors.Type: GrantFiled: December 7, 2007Date of Patent: September 14, 2010Assignee: Atlantos Pharmaceuticals Holding, Inc.Inventors: Christoph Steeneck, Christian Gege, Frank Richter, Heiko Kroth, Matthias Hochgurtel, Michael Essors, Joshua Van Veldhuizen, Bert Nolte, Brian M. Gallagher, Jr., Tim Feuerstein, Matthias Schneider, Torsten Arndt, Hongbo Deng, Ralf Biesinger, Xinyuan Wu, Harald Bluhm, Irving Sucholeiki, Arthur G. Taveras
-
Patent number: 7749996Abstract: The present invention relates generally to azatriocyclic containing pharmaceutical agents, and in particular, to azatricyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of azatricyclic MMP-3, MMP-8 and/or MMP-13 inhibiting compounds, that exhibit an increased potency and selectivity in relation to currently known MMP-13, MMP-8 and MMP-3 inhibitors.Type: GrantFiled: November 20, 2007Date of Patent: July 6, 2010Assignee: Alantos Pharmaceutical Holdings, Inc.Inventors: Christian Gege, Carine Chevrier, Matthias Schneider, Harald Bluhm, Matthias Hochgürtel, Hongbo Deng, Brian M. Gallagher, Jr., Irving Sucholeiki, Arthur Taveras
-
Publication number: 20100087420Abstract: The present invention relates generally to azatriocyclic containing pharmaceutical agents, and in particular, to azatricyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of azatricyclic MMP-3, MMP-8 and/or MMP-13 inhibiting compounds, that exhibit an increased potency and selectivity in relation to currently known MMP-13, MMP-8 and MMP-3 inhibitors.Type: ApplicationFiled: December 4, 2009Publication date: April 8, 2010Applicant: ALANTOS PHARMACEUTICALS HOLDINGS, INC.Inventors: Christian Gege, Carine Chevrier, Matthias Schneider, Harald Bluhm, Matthias Hochgürtel, Hongbo Deng, Brian M. Gallagher, JR., Irving Sucholeiki, Arthur G. Taveras
-
Publication number: 20090312312Abstract: The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic MMP-13 inhibiting and MMP-3 inhibiting compounds, that exhibit an increased potency in relation to currently known MMP-13 and MMP-3 inhibitors.Type: ApplicationFiled: February 12, 2009Publication date: December 17, 2009Applicant: ALANTOS PHARMACEUTICALS HOLDING, INC.Inventors: Christoph STEENECK, Christian GEGE, Frank RICHTER, Heiko KROTH, Matthias HOCHGURTEL, Michael ESSERS, Joshua VAN VELDHUIZEN, Bert NOLTE, Brian M. GALLAGHER, JR., Tim FEUERSTEIN, Matthias SCHNEIDER, Torsten ARNDT, Hongbo DENG, Ralf BIESINGER, Xinyuan WU, Harald BLUHM, Irving SUCHOLEIKI, Arthur G. TAVERAS
-
Publication number: 20090137547Abstract: The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic MMP-13 inhibiting and MMP-3 inhibiting compounds, that exhibit an increased potency in relation to currently known MMP-13 and MMP-3 inhibitors.Type: ApplicationFiled: December 7, 2007Publication date: May 28, 2009Inventors: Christoph Steeneck, Christian Gege, Frank Riohter, Holko Kroth, Mouhlee Hochgueriel, Michael Essors, Joshua Van Veldhulzen, Bert Nolte, Brian M. Gallaghor, JR., Tim Feuerstein, Matthias Schneider, Toralen Arndt, Hongbo Deng, Ralf Blesinger, Xinyuan Wu, Harald Bluhm, Irving Sucholelld, Arthur G. Taverse
-
Publication number: 20080221094Abstract: The present invention relates generally to pharmaceutical agents containing a heterocyclic moiety, and in particular, to heterocyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of heterocyclic MMP-13 inhibiting compounds with a squaramide moiety, that exhibit an increased potency and selectivity in relation to currently known MMP-13 inhibitors.Type: ApplicationFiled: March 7, 2008Publication date: September 11, 2008Inventors: Harald Bluhm, Christian Gege, Matthias Hochgurtel, Arthur Taveras
-
Publication number: 20080221093Abstract: The present invention relates generally to pharmaceutical agents containing a heterocyclic moiety, and in particular, to heterocyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of heterocyclic MMP-13 inhibiting compounds with a benzoxazinone moiety, that exhibit an increased potency and selectivity in relation to currently known MMP-13 inhibitors.Type: ApplicationFiled: March 7, 2008Publication date: September 11, 2008Inventors: Christian Gege, Harald Bluhm, Matthias Hochgurtel, Matthias Schneider, Carine Chevrier, Arthur Taveras
-
Publication number: 20080221092Abstract: The present invention relates generally to amide containing heterobicyclic containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of heterobicyclic MMP-3 and/or MMP-13 inhibiting compounds that exhibit an increased potency and selectivity in relation to currently known MMP-13 and MMP-3 inhibitors.Type: ApplicationFiled: November 20, 2007Publication date: September 11, 2008Inventors: Harald Bluhm, Matthias Hochgurtel, Heiko Kroth, Michael Essers, Christian Gege, Frank Richter, Arthur Taveras
-
Publication number: 20080221083Abstract: The present invention relates generally to amide containing heterobicyclic containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of heterobicyclic MMP-3 and/or MMP-13 inhibiting compounds, that exhibit an increased potency and selectivity in relation to currently known MMP-13 and MMP-3 inhibitors.Type: ApplicationFiled: November 20, 2007Publication date: September 11, 2008Inventors: Matthias Hochgurtel, Harald Bluhm, Heiko Kroth, Michael Essers, Christian Gege, Arthur Taveras
-
Publication number: 20080207607Abstract: The present invention relates generally to azatriocyclic containing pharmaceutical agents, and in particular, to azatricyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of azatricyclic MMP-3, MMP-8 and/or MMP-13 inhibiting compounds, that exhibit an increased potency and selectivity in relation to currently known MMP-13, MMP-8 and MMP-3 inhibitors.Type: ApplicationFiled: November 20, 2007Publication date: August 28, 2008Inventors: Christian Gege, Carine Chevrier, Matthias Schneider, Harald Bluhm, Matthias Hochgurtel, Hongbo Deng, Brian M. Gallagher, Irving Sucholeiki, Arthur Taveras
-
Publication number: 20080161300Abstract: The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic MMP-13 inhibiting and MMP-3 inhibiting compounds, that exhibit an increased potency in relation to currently known MMP-13 and MMP-3 inhibitors.Type: ApplicationFiled: December 7, 2007Publication date: July 3, 2008Applicant: Alantos Pharmaceuticals Holding, Inc.Inventors: Christoph Steeneck, Christian Gege, Frank Richter, Heiko Kroth, Matthias Hochgurtel, Michael Essers, Joshua Van Veldhuizen, Bert Nolte, Brian Gallagher, Tim Feuerstein, Matthias Schneider, Torsten Arndt, Hongbo Deng, Ralf Beisinger, Xinyuan Wu, Harald Bluhm, Irving Sucholeiki, Arthur Taveras
-
Publication number: 20070155739Abstract: This invention relates to substituted bis-amide pyrimidine compounds of Formula (I), which are useful for the treatment of metalloprotease mediated diseases, in particular MMP-13 related diseases.Type: ApplicationFiled: December 28, 2006Publication date: July 5, 2007Inventors: Irving Sucholeiki, Timothy Powers, Christian Gege, Harald Bluhm, Rory Dodd, Hongbo Deng, Xinyuan Wu, Christoph Steeneck
-
Publication number: 20070155737Abstract: The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic ADAMTS-4 inhibiting compounds.Type: ApplicationFiled: November 20, 2006Publication date: July 5, 2007Inventors: Brian Gallagher, Joshua Van Veldhuizen, Xinyuan Wu, Hongbo Deng, Irving Sucholeiki, Matthias Hochguertel, Harald Bluhm, Arthur Taveras
-
Publication number: 20070155738Abstract: The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic MMP-13 inhibiting and MMP-3 inhibiting compounds, that exhibit an increased potency in relation to currently known MMP-13 and MMP-3 inhibitors.Type: ApplicationFiled: November 20, 2006Publication date: July 5, 2007Inventors: Christoph Steeneck, Christian Gege, Frank Richter, Heiko Kroth, Matthias Hochguertel, Michael Essers, Joshua Van Veldhuizen, Bert Nolte, Brian Gallagher, Tim Feuerstein, Matthias Schneider, Torsten Arndt, Hongbo Deng, Ralf Biesinger, Xinyuan Wu, Harald Bluhm, Irving Sucholeiki, Arthur Taveras
-
Publication number: 20060293345Abstract: The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic MMP-13 inhibiting compounds, that exhibit an increased potency in relation to currently known MMP-13 inhibitors.Type: ApplicationFiled: May 22, 2006Publication date: December 28, 2006Inventors: Christoph Steeneck, Christian Gege, Frank Richter, Matthias Hochguertel, Tim Feuerstein, Harald Bluhm, Irving Sucholeiki, Jurgen Boer, Xinyuan Wu, Matthias Schneider, Bert Nolte, Brian Gallagher, Joshua Van Veldhuizen, Hongbo Dong, Michael Essers, Heiko Kroth, Andrew Kiely, Timothy Powers, Arthur Taveras
-
Publication number: 20060173183Abstract: The present invention relates generally to bis-amide group containing pharmaceutical agents, and in particular, to multicyclic bis-amide MMP-13 inhibitor compounds. More particularly, the present invention provides a new class of MMP-13 inhibiting compounds, containing a pyrimidinyl bis-amide group in combination with a heterocyclic moiety, that exhibit an increased potency and solubility in relation to currently known bis-amide group containing MMP-13 inhibitors.Type: ApplicationFiled: December 30, 2005Publication date: August 3, 2006Inventors: Timothy Powers, Christoph Steeneck, Ralf Biesinger, Harald Bluhm, Hongbo Deng, Rory Dodd, Brian Gallagher, Christian Gege, Matthias Hochgurtel, Andrew Kiely, Frank Richter, Matthias Schneider, Irving Sucholeiki, Joshua Van Veldhuizen, Xinyuan Wu, Arthur Taveras